None listed
Conditions
Brief summary
This is a study aiming to evaluate whether metformin, an antidiabetic medication, can be used safety and effectively in patients with type 2 diabetes who are receiving haemodialysis for their end stage kidney disease. The study runs over 4 weeks and 500mg of metformin (one tablet) will be given to participants after each dialysis session in weeks 2-4 of the study (9 times). We hypothesise that metformin can be safely used in patients with type 2 diabetes with end stage renal failure if dosed based on predicted drug clearance.
Interventions
Metformin dosed orally at 500mg within one hour post each haemodialysis session for 3 weeks (after 9 dialysis sessions)
Sponsors
Dr Tilenka Thynne
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
> 18 years Type 2 Diabetes Receiving haemodialysis 3 times a week for greater than 3 months Patients in which metformin would normally be used if they had normal renal function. Consent
Exclusion criteria
(1)Any patients in whom metformin would not be used in the setting of normal renal function including: Moderate to severe heart failure, liver failure, alcohol abuse, major psychiatric disorder, acutely unwell or otherwise medically unstable. (2)Unable or unwilling to self monitor and record blood glucose levels via glucometer readings. (3)Inability to provide written informed consent.
Outcome results
None listed